FDA Approved: VONJO — Supplemental Application (Sobi, Inc.)

View source ↗

Summary

The FDA approved a supplemental application for VONJO (pacritinib) from Sobi, Inc., expanding its labeling for the treatment of adults with myelofibrosis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelofibrosis

Drugs mentioned

• VONJO (pacritinib)

Snippet

SUPPL AP for VONJO (PACRITINIB)